EU approves Imvanex vaccine for Smallpox

Bavarian Nordic A/S announced on 7 August 2013 that the European Commission has granted marketing authorization for Imvanex (MVA-BN) for active immunization against Smallpox disease for the general adult population, including people with weakened immune systems (people diagnosed with HIV or atopic dermatitis). The authorization covers all 27 European Union member states and European Economic Area countries Iceland, Liechtenstein and Norway.Imvanex will be made available for governments to purchase and use in accordance with official national recommendations.

Imvanex is the only smallpox vaccine approved through the centralized procedure and available to all EU member states. Known as Imvamune in the U.S., it has been developed under contracts with the U.S. Government.